Schjesvold F, Paiva B, Ribrag V, Rodriguez-Otero P, San-Miguel JF, Robak P, Hansson M, Onishi M, Hamidi H, Malhi V, Dail M, Javery A, Ku G, Raab MS (2022)
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clin Lymphoma Myeloma Leuk (in press)
DOI 10.1016/j.clml.2022.10.006, PubMed 36450626

Schjesvold FH, Bakker NA, Sonneveld P (2022)
Authors' reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
Transl Oncol, 25, 101528
DOI 10.1016/j.tranon.2022.101528, PubMed 36087383

Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG (2022)
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
Ann Hematol, 101 (10), 2123-2137
DOI 10.1007/s00277-022-04917-5, PubMed 35943588